How Much Does Rezdiffra (Resmetirom) Cost in Montana in 2026?

Rezdiffra Retail Pricing in Montana

The cash-pay price for brand-name Rezdiffra at Montana retail pharmacies averages $3,500 per month in 2026, matching the manufacturer list price set by Madrigal Pharmaceuticals. That figure applies to a 30-day supply of once-daily tablets at either the 80 mg or 100 mg strength.

Rezdiffra is the first and only FDA-approved thyroid hormone receptor beta (THR-β) agonist for metabolic dysfunction-associated steatohepatitis (MASH, formerly called NASH) with moderate-to-advanced liver fibrosis. The FDA granted accelerated approval in March 2024 based on the MAESTRO-NASH trial, which demonstrated MASH resolution without worsening fibrosis in 25.9% of patients on the 80 mg dose and 29.9% on the 100 mg dose at 52 weeks, compared with 9.7% for placebo [1]. Because no generic version exists and Madrigal holds market exclusivity, Montana patients face uniform pricing across retail outlets.

Pharmacy markup varies little. Independent pharmacies in Billings, Missoula, and Great Falls price Rezdiffra within $50 of the $3,500 list. Large chains match that figure exactly. Patients without insurance or discount programs should expect the full amount.

Montana Medicaid Does Not Cover Rezdiffra

As of 2026, Montana Medicaid has not added Rezdiffra to its preferred drug list. Patients enrolled in Medicaid or the Montana HELP Plan (the state's Medicaid expansion program) cannot obtain coverage for this medication through standard formulary channels.

This gap is not unique to Montana. Most state Medicaid programs have been slow to add Rezdiffra, partly because the drug received accelerated approval from the FDA rather than traditional approval. Accelerated approval means confirmatory trial data (from MAESTRO-NASH's ongoing extension) must still verify the drug's long-term clinical benefit on liver-related outcomes [2]. Medicaid formulary committees in multiple states have cited this pending confirmation as a reason for deferral.

Montana Medicaid does allow exception requests. A prescriber can submit a prior authorization with supporting documentation showing a patient has biopsy-confirmed MASH with F2 or F3 fibrosis. Approval through this pathway is uncommon but not impossible. According to the American Association for the Study of Liver Diseases (AASLD) practice guidance, liver biopsy remains the reference standard for staging fibrosis, though noninvasive tests like FibroScan and FIB-4 scores are increasingly accepted for treatment decisions [3].

Dr. Zobair Younossi, Chair of the Global NASH Council, has stated: "The economic burden of NASH in the United States exceeds $100 billion annually when accounting for direct medical costs and lost productivity. Restricting access to the first approved therapy will shift costs downstream into transplant and decompensated cirrhosis care."

Commercial Insurance Coverage in Montana

Several commercial plans operating in Montana have begun covering Rezdiffra, though all require prior authorization and step therapy documentation. Blue Cross Blue Shield of Montana, PacificSource, and Allegiance Benefit Plan Management each list Rezdiffra under specialty pharmacy tiers with specific criteria.

Typical requirements for approval include: a confirmed diagnosis of MASH with liver fibrosis staged at F2 or F3 (via biopsy or validated noninvasive score), documentation that the patient has attempted lifestyle modifications for at least six months, and prescription by or in consultation with a hepatologist or gastroenterologist. Some plans also require a baseline FIB-4 score or vibration-controlled transient elastography (VCTE) result.

The specialty tier copay for Rezdiffra on commercial plans in Montana typically ranges from $150 to $500 per month after the plan's contribution, though this varies by specific plan design and deductible status. Patients on high-deductible health plans may face the full $3,500 until their deductible is met.

The MAESTRO-NASH trial also showed that resmetirom reduced hepatic fat content by approximately 45% at the 100 mg dose as measured by MRI-proton density fat fraction, compared with a 10% reduction in the placebo group [1]. This imaging endpoint is sometimes requested by insurers as a baseline measurement before authorizing coverage.

The Madrigal Pharmaceuticals Savings Card

Madrigal offers a copay assistance program for commercially insured patients that can reduce out-of-pocket costs to as little as $0 per month, with a maximum annual benefit. The program is available to Montana residents who carry commercial (non-government) insurance.

Here is how the card works. Patients or prescribers enroll through the Madrigal Rezdiffra support website or by calling the manufacturer's patient services line. Once enrolled, the savings card is applied at the dispensing specialty pharmacy. The card covers the difference between the patient's copay or coinsurance and $0, up to the program's annual cap. Eligibility is verified at each fill.

Key restrictions apply. The savings card cannot be used by patients enrolled in Medicare, Medicaid, TRICARE, or any other federal or state government-funded program. Montana patients on the Montana HELP Plan (Medicaid expansion) are not eligible. The card also does not apply to cash-pay patients who lack any commercial insurance.

For the commercially insured Montana patient facing a $300-per-month specialty copay, the savings card effectively eliminates that cost. This makes brand Rezdiffra financially accessible to a subset of patients who might otherwise struggle with the specialty tier pricing.

Compounded Resmetirom Through 503A Pharmacies in Montana

Montana permits compounding of resmetirom through licensed 503A pharmacies. A 503A pharmacy operates under Section 503A of the Federal Food, Drug, and Cosmetic Act, which allows patient-specific compounding based on a valid prescription [4]. This is a legal pathway in Montana, and multiple compounding pharmacies in the state have the capability to prepare resmetirom formulations.

A critical distinction. Compounded resmetirom is not FDA-approved Rezdiffra. The compounded version is prepared from bulk active pharmaceutical ingredient (API) and may differ in formulation, bioavailability, and excipients from the branded tablet. The FDA's guidance on compounding emphasizes that compounded drugs do not undergo the same premarket review for safety, efficacy, and manufacturing quality as approved drugs [4].

Compounded resmetirom pricing through 503A pharmacies in Montana is substantially lower than the brand product. Some 503A pharmacies advertise resmetirom capsules for MASH at prices that represent a fraction of the $3,500 brand cost. Patients considering this route should confirm that the compounding pharmacy holds a valid Montana Board of Pharmacy license and uses USP-compliant processes.

The American Association of Clinical Endocrinology (AACE) has noted in its 2023 clinical practice guideline on obesity and MASH that thyroid hormone receptor agonists represent a targeted mechanism distinct from weight loss alone, acting directly on hepatocyte lipid metabolism and fibrogenesis [5]. This mechanism-specific action underscores why some clinicians prefer the FDA-approved formulation with known pharmacokinetic properties over compounded alternatives.

Telehealth Prescribing of Rezdiffra in Montana

Montana allows telehealth prescribing of Rezdiffra. A physician licensed in Montana can evaluate a patient via synchronous video visit, review relevant labs and imaging, and issue a prescription without requiring an in-person encounter first.

This matters for Montana specifically. The state spans 147,040 square miles with a population of roughly 1.1 million. Hepatologists and gastroenterologists concentrate in Billings, Missoula, and Great Falls. Patients in rural eastern Montana or in communities along the Hi-Line corridor may live three or more hours from the nearest specialist.

Telehealth removes that barrier. A Montana patient with a confirmed MASH diagnosis can consult with an in-state or multi-state-licensed hepatologist, obtain a Rezdiffra prescription, and have it filled through a specialty or compounding pharmacy that ships to their address.

Montana's telehealth parity law (Montana Code Annotated § 33-22-138) requires commercial insurers to cover telehealth services at the same rate as in-person visits, though this does not guarantee formulary coverage of the prescribed drug itself. The prescription still must meet the insurer's prior authorization criteria.

How Rezdiffra Compares to Other MASH Treatments

Rezdiffra occupies a narrow but significant niche. Before its approval, no FDA-approved pharmacotherapy existed for MASH. Treatment relied on weight loss (typically 7-10% of body weight to achieve histologic improvement), vitamin E (limited to non-diabetic patients with biopsy-confirmed NASH, per AASLD guidance), and off-label use of pioglitazone [3].

GLP-1 receptor agonists, particularly semaglutide, have shown benefit in MASH. The NEJM-published semaglutide trial (N=320) demonstrated NASH resolution in 59% of patients on semaglutide 0.4 mg daily versus 17% on placebo at 72 weeks [6]. Semaglutide for MASH (at the higher dose) is not yet FDA-approved for this specific indication, though it carries approval for type 2 diabetes and obesity.

Resmetirom works through a different mechanism: selective activation of THR-β in the liver. This reduces intrahepatic lipid content, lowers atherogenic lipoproteins, and appears to directly reduce fibrogenic signaling. In MAESTRO-NASH, patients on the 100 mg dose achieved a 22% relative reduction in LDL cholesterol compared with placebo, an effect not seen with GLP-1 agonists to the same degree [1]. For Montana patients already on a GLP-1 for obesity or diabetes, resmetirom may offer complementary hepatic benefit rather than a competing pathway.

The cost comparison is relevant. Semaglutide (Wegovy) lists at approximately $1,350 per month, while resmetirom (Rezdiffra) lists at $3,500 per month. Tirzepatide (Zepbound) carries a list price near $1,060 per month. A patient pursuing both weight loss and direct MASH treatment faces combined monthly costs that make insurance coverage or manufacturer assistance programs essential.

Strategies to Reduce Your Rezdiffra Cost in Montana

Montana patients have several concrete options to lower their out-of-pocket expense for resmetirom.

Use the Madrigal CoPay Card. If you have commercial insurance, enroll in the manufacturer's copay program. This is the single most effective cost-reduction tool for insured patients.

Request a peer-to-peer review. If your insurer denies prior authorization, ask your prescriber to conduct a peer-to-peer call with the plan's medical director. Denials based on "insufficient evidence" can sometimes be overturned when the prescriber presents the MAESTRO-NASH data directly. The trial enrolled patients with F1B through F3 fibrosis and NAS score ≥ 4, and the primary endpoints were met with statistical significance (P<0.001 for both MASH resolution and fibrosis improvement) [1].

Ask about patient assistance. Madrigal's Rezdiffra patient support program includes a free drug program for uninsured patients who meet income criteria. Eligibility is assessed on a case-by-case basis.

Consider compounded resmetirom. If brand Rezdiffra is financially out of reach and you lack qualifying insurance, a 503A compounded formulation is a legal option in Montana. Discuss the trade-offs with your hepatologist.

Explore clinical trials. The ongoing MAESTRO-NASH extension study and other Madrigal-sponsored trials may provide access to resmetirom at no cost. ClinicalTrials.gov lists active recruitment sites; while Montana-based sites are limited, some trials permit remote participation with periodic in-person assessments at regional centers.

What Montana Patients Should Know About Monitoring

Rezdiffra requires specific lab monitoring. The FDA prescribing information recommends thyroid function tests (TSH and free T4) before starting treatment and periodically during therapy [2]. Resmetirom selectively targets THR-β, which spares the cardiac THR-α receptor, but suppression of TSH can still occur and must be tracked.

Liver function tests (ALT, AST, bilirubin) should be checked at baseline and during treatment. In MAESTRO-NASH, ALT levels decreased significantly in the resmetirom groups compared with placebo, reflecting reduced hepatic inflammation [1]. A paradoxical rise in transaminases after starting treatment warrants prompt evaluation.

Lipid panels are also indicated. Resmetirom's LDL-lowering effect (approximately 14-16% reduction from baseline at the 100 mg dose in MAESTRO-NASH) may allow dose adjustment or discontinuation of concurrent lipid-lowering therapy in some patients [1].

Dosing is weight-based: 80 mg once daily for patients weighing <100 kg, and 100 mg once daily for patients weighing ≥100 kg. The tablet is taken with food.